The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), the Manufacturing USA institute headquartered at UD, is pleased to announce it has released its first full project call. Project Call 1.0 requests proposals that address technology and/or workforce development issues in biopharmaceutical manufacturing.

NIIMBL fosters collaboration between industry, academia and federal agencies in developing innovative technologies to advance U.S. biopharmaceutical manufacturing. In addition to new technologies, NIIMBL also addresses workforce development issues and supports the development of standards that enable more efficient manufacturing capabilities.

As part of Project Call 1.0, NIIMBL plans to make up to $8 million available to fund multiple projects. Proposals are permitted a maximum project duration of 18 months, may request up to $1 million per year in NIIMBL funds, and have a cost share requirement, which is based on the total funding requested.  UD investigators can request cost share resources in addition to cost share from their college or department. For more information, please contact Marta Rosario at martar@udel.edu.

The Request for Proposals (RFP) and submission guidelines can be found at http://niimbl.org/projectCall.php. The RFP provides a detailed list of Priority Funding Areas developed from input by NIIMBL industry members.

Proposal teams are required to submit a non-binding Notice of Intent by Jan. 16, 2018. Final proposals are due Friday, Jan. 26, 2018.

Key Dates

Dec. 22, 2017 – Deadline to request state cost share. Please contact Marta Rosario at martar@udel.edu.

Jan. 16 – Non-binding notice of intent due by 5:00 pm EST.

Jan. 26 – Final proposals due by 5:00 pm EST.

For more information, please contact projectcalls@niimbl.org.

About NIIMBL

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is a public-private consortium dedicated to advancing biopharmaceutical manufacturing innovation in the U.S. The NIIMBL mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry.